What's Wrong With UnitedHealth Stock?

UnitedHealth reported Q4 adjusted EPS of $2.11 versus $2.10 consensus while revenue missed at $113.2 billion versus $113.82 billion expected. Management guided 2026 revenue to roughly $439 billion (about a 2% year-over-year decline) and cited rising utilization and higher medical costs, while the administration’s proposed 2027 Medicare Advantage rate increase of just 0.09% (vs. ~4% expected by analysts) creates an additional industry headwind—pressure that has contributed to heavy selling (stock down ~13% YTD and ~35% in 2025).

Analysis

Market structure: The proposed Medicare Advantage (MA) rate (+0.09% vs street +4%) and UNH’s -2% 2026 revenue guide shift margin power away from large insurers (UNH, HUM, CVS) and toward providers and margin-stable franchises (hospitals, specialty pharma). Expect accelerated price competition for MA plan wins and smaller membership churn wins for low-cost competitors; industry revenue growth likely lags medical cost inflation by 200–400 bps in 2026 absent offsetting actions.

Risk assessment: Near-term (days–weeks) risk is continued equity repricing and higher implied vol; medium-term (60–180 days) risk centers on the CMS final rule, Q1 membership trends and risk-adjustment collections; tail risks include an unexpected final CMS cut >1% or a shock rise in utilization (+300 bps) that forces additional reserves. Hidden dependency: Optum services and risk‑adjustment receipts are non-linear buffers — if those underperform, downside amplifies.

Trade implications: Trade around two actionable windows — CMS finalization (~30–60 days) and Q1 earnings (~60–90 days). Favor defined‑risk bearish positions on UNH (put spreads sized to 0.5–1.0% portfolio risk) and pair trades long hospitals (HCA) vs short managed care (UNH) for 3–6 months; rotate 2–4% allocation from pure managed‑care beta into hospital/pharma defensives.

Contrarian angles: The market may be over-discounting Optum’s margin resilience and potential for higher-than-proposed final MA rates; if CMS final rule reverts to +1% or UNH reiterates cost controls, expect a snapback of 15–25% in 1–3 months. Beware of crowded short positioning and buyback/insurer capital returns that can cap downside — therefore prefer capped-loss option structures, not naked shorts.

Key Decisions for Investors

• Establish a defined‑risk bearish position on UNH: buy a 60–90 day put spread (long 20% OTM, short 10% OTM) sized to risk 0.5–1.0% of portfolio, close if UNH falls 15% (take profits) or if CMS final MA rate > +1.0% (cover).
• Initiate a 3–6 month relative‑value pair: go long HCA (2% notional) and short UNH (2% notional). Rationale: hospital reimbursement resilience vs managed‑care margin compression; target relative outperformance of 10–15% and reassess at 90 days.
• Reduce aggregate managed‑care exposure (UNH/HUM/CVS) by ~50% of current weight over 2 weeks; redeploy into hospital operators (HCA) and large-cap pharma (e.g., MRK) until CMS final rule and Q1 medical-cost trends are clear.
• Monitor (and set alerts for) three triggers: CMS final MA rate publication (expected within 30–60 days), UNH Q1 earnings and risk‑adjustment receipts (within 60–90 days), and industry utilization delta > +200 bps; these should prompt re‑rating or exiting of bearish positions.